Matches in SemOpenAlex for { <https://semopenalex.org/work/W3125974985> ?p ?o ?g. }
- W3125974985 endingPage "1172" @default.
- W3125974985 startingPage "1165" @default.
- W3125974985 abstract "The response to vaccines in juvenile idiopathic arthritis (JIA) patients on and off anti-tumor necrosis factor (anti-TNF) agents remains highly discussed. There are no published studies on the immune response following a Tdap booster dose in JIA patients so far.To evaluate the immune response and safety after a Tdap booster in JIA patients and in healthy adolescents.Nineteen adolescents with JIA according to the ILAR criteria on anti-TNF medication, 19 adolescents with JIA off anti-TNF medication, and 27 healthy adolescents (control group) were compared after a Tdap booster. Adverse events and disease activity were evaluated. Lymphocyte immunophenotyping was performed by flow cytometry. Tetanus, diphtheria and pertussis toxin antibodies were assessed by ELISA; whole blood was stimulated with whole-cell pertussis, and supernatants were assessed for cytokines by xMAP.The three groups showed a similar frequency of adverse events. There was no disease reactivation after the Tdap booster. Tetanus, diphtheria and pertussis antibodies showed a significant response when D0 and D14 concentrations were compared in both JIA groups and controls. Over time, a different pattern of response to the Tdap booster was observed among the groups for tetanus antibodies (p = 0.005) but not for diphtheria and pertussis antibodies. In contrast to the protection attained for tetanus and diphtheria, in the three groups, not all individuals showed pertussis seroconversion at either D14 or D28. In addition, the seroconversion of three subjects with JIA on anti-TNF medication was not maintained at D28. JIA patients off anti-TNF showed a higher percentage of naive CD8 + T cells (p = 0.007) and central memory CD8 + cells (p = 0.003) and a lower percentage of effector CD8 + T cells (p = 0.003) and NK cell numbers (p = 0.018) than the control group. The JIA group off anti-TNF medication had fewer B lymphocytes than both the JIA group on anti-TNF medication and the control group (p = 0.016). Cellular immunity to Bordetella pertussis showed that IFNγ levels were significantly lower in both JIA groups than in the control group (p = 0.003), IL10 levels were higher in the JIA off anti-TNF group (p = 0.009), IL17A and IL5 levels were lower in the JIA on anti-TNF group than in the control group (p = 0.018 and p = 0.016, respectively); however, an increase in IFNγ (p = 0.008), IL17A (p = 0.030) and TNFα (p = 0.041) levels was observed at D14 in both patient groups. Both JIA groups showed higher levels of IL21 than the control group (p = 0.023).We conclude that individuals with JIA on or off anti-TNF agents showed a good response to a booster dose for the three antigens studied in the absence of major adverse events and without the reactivation of the disease." @default.
- W3125974985 created "2021-02-01" @default.
- W3125974985 creator A5005974005 @default.
- W3125974985 creator A5017238552 @default.
- W3125974985 creator A5067610116 @default.
- W3125974985 creator A5075225770 @default.
- W3125974985 creator A5076649663 @default.
- W3125974985 creator A5082736892 @default.
- W3125974985 creator A5089162243 @default.
- W3125974985 date "2021-02-01" @default.
- W3125974985 modified "2023-10-02" @default.
- W3125974985 title "Tdap booster to adolescents with juvenile idiopathic arthritis on and off anti-TNF agents is safe and immunogenic" @default.
- W3125974985 cites W1540943134 @default.
- W3125974985 cites W1767403706 @default.
- W3125974985 cites W1964853179 @default.
- W3125974985 cites W1974096487 @default.
- W3125974985 cites W1979383005 @default.
- W3125974985 cites W1983054016 @default.
- W3125974985 cites W1998562159 @default.
- W3125974985 cites W2013703920 @default.
- W3125974985 cites W2020452602 @default.
- W3125974985 cites W2024264416 @default.
- W3125974985 cites W2027697804 @default.
- W3125974985 cites W2036463856 @default.
- W3125974985 cites W2041313976 @default.
- W3125974985 cites W2049128837 @default.
- W3125974985 cites W2052539517 @default.
- W3125974985 cites W2094340925 @default.
- W3125974985 cites W2136550752 @default.
- W3125974985 cites W2150630714 @default.
- W3125974985 cites W2154652582 @default.
- W3125974985 cites W2167450052 @default.
- W3125974985 cites W2174328319 @default.
- W3125974985 cites W2498168571 @default.
- W3125974985 cites W2512179350 @default.
- W3125974985 cites W2743363932 @default.
- W3125974985 cites W2800203083 @default.
- W3125974985 cites W2885541611 @default.
- W3125974985 cites W4234967311 @default.
- W3125974985 doi "https://doi.org/10.1016/j.vaccine.2020.12.071" @default.
- W3125974985 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33478788" @default.
- W3125974985 hasPublicationYear "2021" @default.
- W3125974985 type Work @default.
- W3125974985 sameAs 3125974985 @default.
- W3125974985 citedByCount "1" @default.
- W3125974985 countsByYear W31259749852023 @default.
- W3125974985 crossrefType "journal-article" @default.
- W3125974985 hasAuthorship W3125974985A5005974005 @default.
- W3125974985 hasAuthorship W3125974985A5017238552 @default.
- W3125974985 hasAuthorship W3125974985A5067610116 @default.
- W3125974985 hasAuthorship W3125974985A5075225770 @default.
- W3125974985 hasAuthorship W3125974985A5076649663 @default.
- W3125974985 hasAuthorship W3125974985A5082736892 @default.
- W3125974985 hasAuthorship W3125974985A5089162243 @default.
- W3125974985 hasConcept C121332964 @default.
- W3125974985 hasConcept C12590561 @default.
- W3125974985 hasConcept C126322002 @default.
- W3125974985 hasConcept C1276947 @default.
- W3125974985 hasConcept C159654299 @default.
- W3125974985 hasConcept C197934379 @default.
- W3125974985 hasConcept C203014093 @default.
- W3125974985 hasConcept C203165030 @default.
- W3125974985 hasConcept C22070199 @default.
- W3125974985 hasConcept C2777077863 @default.
- W3125974985 hasConcept C2777451964 @default.
- W3125974985 hasConcept C2779841045 @default.
- W3125974985 hasConcept C2780572238 @default.
- W3125974985 hasConcept C2780801004 @default.
- W3125974985 hasConcept C71924100 @default.
- W3125974985 hasConcept C8891405 @default.
- W3125974985 hasConceptScore W3125974985C121332964 @default.
- W3125974985 hasConceptScore W3125974985C12590561 @default.
- W3125974985 hasConceptScore W3125974985C126322002 @default.
- W3125974985 hasConceptScore W3125974985C1276947 @default.
- W3125974985 hasConceptScore W3125974985C159654299 @default.
- W3125974985 hasConceptScore W3125974985C197934379 @default.
- W3125974985 hasConceptScore W3125974985C203014093 @default.
- W3125974985 hasConceptScore W3125974985C203165030 @default.
- W3125974985 hasConceptScore W3125974985C22070199 @default.
- W3125974985 hasConceptScore W3125974985C2777077863 @default.
- W3125974985 hasConceptScore W3125974985C2777451964 @default.
- W3125974985 hasConceptScore W3125974985C2779841045 @default.
- W3125974985 hasConceptScore W3125974985C2780572238 @default.
- W3125974985 hasConceptScore W3125974985C2780801004 @default.
- W3125974985 hasConceptScore W3125974985C71924100 @default.
- W3125974985 hasConceptScore W3125974985C8891405 @default.
- W3125974985 hasFunder F4320320997 @default.
- W3125974985 hasFunder F4320322025 @default.
- W3125974985 hasIssue "7" @default.
- W3125974985 hasLocation W31259749851 @default.
- W3125974985 hasLocation W31259749852 @default.
- W3125974985 hasOpenAccess W3125974985 @default.
- W3125974985 hasPrimaryLocation W31259749851 @default.
- W3125974985 hasRelatedWork W1998512536 @default.
- W3125974985 hasRelatedWork W2012925344 @default.
- W3125974985 hasRelatedWork W2015712765 @default.
- W3125974985 hasRelatedWork W2027431547 @default.
- W3125974985 hasRelatedWork W2056999367 @default.